# Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹82.03
Day Change: -3.56%
52W High: ₹100
52W Low: ₹49.01
Market Cap: ₹258 Cr

## Valuation
P/E: 74.58
P/B: 1.71
EPS: ₹1.22
Book Value: ₹53.06
Dividend Yield: 0%

## Returns
1Y Return: -8.65%

## Profitability
ROE: 0%
ROCE: 0.68%
Debt/Equity: 0.38
Revenue Growth: -27.9%
Profit Growth: -21.9%
EBITDA Margin: 0.64%
Operating Margin: -2.43%

## About
Aarey Drugs & Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Aarey Drugs & Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Announcement: Closure of Trading Window
- BSE Filing: Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

## Access
Current tier: anonymous
More history: Register free to see 1 more year.

## Data Freshness
Quote Updated: 2026-05-21T20:00:00.502Z
Price History Updated: 2026-05-17T21:23:44.339Z
Latest Price History Date: 2026-05-17
Technicals Updated: 2026-05-17T21:23:44.339Z
Quant Updated: 2026-05-17T21:23:44.339Z
Sentiment Updated: 2026-05-17T21:23:44.339Z
Financials Status: current
Financials Updated: 2026-05-18T23:01:49.440Z
Financials Last Attempt: 2026-05-18T23:01:49.440Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (FY25)
Revenue: ₹472.24 Cr
Operating Profit: ₹0.81 Cr (OPM 0.17%)
Net Profit: ₹4.02 Cr
Tax: ₹2.08 Cr

## Annual P&L History
FY25: Rev ₹472.24Cr | PAT ₹4.02Cr | OPM 0.17%
FY24: Rev ₹395.1Cr | PAT ₹4.68Cr | OPM 0.71%
FY23: Rev ₹412.85Cr | PAT ₹3.77Cr | OPM 0.48%

## Balance Sheet (FY25)
Total Assets: ₹290.59 Cr
Total Liabilities: ₹152.11 Cr
Borrowings: ₹34.86 Cr
Cash: ₹1.47 Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Mihir Rajesh Ghatalia B.E, Chairman & MD
- Nimit Rajesh Ghatalia, Executive Director
- Mira Mihir Ghatalia, Chief Financial Officer
- A. S. Kathawala, Chief Accountant
- Kailash Chand Jethlia, Company Secretary & Compliance Officer

---
Source: rupiya.io/stocks/aareydrugs
Disclaimer: For research and education only. Not investment advice.